Hexanoylglycine as biomarker for the predisposition for weight gain and obesity
View Patent ↗The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be hexanoylglycine.
1. A method of diagnosing the likelihood of a subject to resist high fat diet induced weight gain, the method comprising:
determining the level of hexanoylglycine in a urine sample previously obtained from a subject to be tested, and
comparing the subject's hexanoylglycine level to a predetermined reference value,
wherein the predetermined reference value is based on an average hexanoylglycine level in urine in a control population, and
wherein an increased hexanoylglycine level in the sample compared to the predetermined reference value indicates an increased likelihood to resist high fat diet induced weight gain.
2. The method of claim 1 , further comprising the steps of
determining the level of at least one further biomarker selected from the group consisting of trimethylamine-N-oxide, isovalerylglycine, leucine, isobutyrate, acetate, guanidoacetate, sucrose, tartaric acid, hippuric acid and hydroxyphenylacetylglycine in the urine sample, and
comparing the subject's level of the at least one further biomarker to a predetermined reference value,
wherein the predetermined reference value is based on average levels of that at least one further biomarker in a urine sample of a normal healthy control population, and
wherein an increased isovalerylglycine, leucine, acetate, and/or a decreased trimethylamine-N-oxide, guanidoacetate, sucrose, tartaric acid, hippuric acid and/or hydroxyphenylacetylglycine level in the urine sample compared to the predetermined reference values indicates an increased likelihood to resist high fat diet induced weight gain.
3. The method of claim 1 , wherein the levels of the biomarkers are determined by 1 H-NMR and/or mass spectrometry in the sample and in the reference.
4. The method of claim 1 , wherein a decreased likelihood to resist high fat diet induced weight gain is indicative for the likelihood to develop disorders associated with overweight and/or obesity.
5. The method of claim 4 , wherein the disorders associated with overweight and/or obesity are cardio metabolic diseases and/or metabolic deregulations.
6. The method of claim 1 , wherein the subject is underweight, normal, overweight, or obese.
7. The method of claim 1 , wherein the subject is a human or a companion animal.
8. The method of claim 1 , wherein a decreased likelihood to resist high fat diet induced weight gain is indicative for a lack of specific activation of mitochondrial oxidative pathways.
9. The method of claim 1 , wherein an increased likelihood to resist high fat diet induced weight gain is indicative for a specific activation of mitochondrial oxidative pathways.
10. The method of claim 8 , wherein the mitochondrial oxidative pathways are selected from the group consisting of β oxidation, butanoate metabolism and leucine catabolism.
11. The method of claim 1 , wherein the subject is a child, a teenager, a young adult and/or a person at risk of developing overweight or obesity.
12. The method of claim 1 , wherein the method is used to devise a stratified diet for a specific group of subjects or a personalized diet for a specific subject.
13. The method of claim 7 , wherein the companion animal is a cat or a dog.